Results 51 to 60 of about 170,256 (261)

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis

Frontiers in Oncology, 2022
BackgroundPembrolizumab and cemiplimab have been approved as treatment for advanced non-small-cell lung cancer (NSCLC) with high programmed death ligand-1 (PD-L1) expression.
Yan Li, Xueyan Liang, Tong Yang, Tong Yang, Sitong Guo, Xiaoyu Chen   +5 more
doaj   +1 more source

Pembrolizumab (Keytruda)

, 2016
The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells.
Kwong, YL, Tse, EWC, Yau, TCC, Chiu, WYJ, Kwok, G   +4 more
core   +1 more source

Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer

Advanced Science, EarlyView.
This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang   +9 more
wiley   +1 more source

Immunogenicity of pembrolizumab in patients with advanced tumors

Journal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug
Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater   +14 more
doaj   +1 more source

Multi‐Omics Integration Identifies a CDH3‐Associated Malignant Epithelial State and Immunosuppressive Niche to Predict Prognosis in Thymic Epithelial Tumors

Advanced Science, EarlyView.
Single‐cell, spatial, molecular, and pathology analyses identify a CDH3‐associated malignant epithelial state in thymic epithelial tumors. This state links stem‐like and EMT programs to M2 macrophage–rich immunosuppressive niches, genomic instability, poor survival, and drug vulnerability.
Yuntao Feng, Jingyu Chen, Lang Xia, Tao Wang, Yuzhou Wang, Lei Zhang, Guofang Zhao, Long Xu, Juemin Yu, Yunlang She, Junqi Wu, Yue Zhao, Chang Chen, Deping Zhao   +13 more
wiley   +1 more source

Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models

Advanced Science, EarlyView.
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu, Ling Li, Sachin S. Surwase, Xin Ming M. Zhou, Hongtao Qian, Joel C. Sunshine, Florin M. Selaru, Jordan J. Green   +7 more
wiley   +1 more source

Pembrolizumab-induced necrotizing diaphragmatic myositis

Pembrolizumab, an anti-PD1 antibody, is increasingly used for the treatment of non-small cell lung cancer. We report a severe and poorly described adverse effect of this therapy: necrotizing myopathy with diaphragmatic and myocardial involvement.
Noemí Vidal, Enric Prats, Carla Marco, David Rodríguez-Plaza   +3 more
core   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

Tumor Lysis Syndrome Due to Pembrolizumab Use in Metastatic Nasopharyngeal Carcinoma

In this case, we report tumor lysis syndrome (TLS) in a patient with metastatic nasopharyngeal carcinoma treated with pembrolizumab. There are only a few studies reporting the development of TLS associated with pembrolizumab, but this is the first report
ÇAĞLAR, ALPEREN AKANSEL, Mehmet Bilici, Alperen Akansel Çağlar, BÜYÜKBAYRAM, MEHMET EMİN, Aykut Turhan, TEKİN, SALİM BAŞOL, Zekeriya Hannarici, TURHAN, AYKUT, Salim Başol Tekin, ÇOBAN EŞDUR, PINAR, Mehmet Emin Büyükbayram, HANNARİCİ, ZEKERİYA, Pınar Çoban Eşdur, BİLİCİ, MEHMET   +13 more
core   +1 more source

Renal toxicities associated with pembrolizumab

, 2019
International audienceObjective : Expanded clinical experience with patients treated by pembrolizumab has accumulated. However, renal toxicities associated with this anti-programmed cell death 1 agent are poorly described because kidney histology is ...
Michels, Judith, Izzedine, Hassan, Varga, Andrea, Malka, David, Soria, Jean-Charles, Champiat, Stéphane, Marabelle, Aurélien, Mathian, Alexis, Amoura, Zahir, Picard, Cécile, Routier, Emilie, Kaaki, Sihem, Goujon, Jean-Michel, Lambotte, Olivier, Brochériou, Isabelle, Mateus, Christine, Quellard, Nathalie, Leary, Alexandra, Michot, Jean-Marie   +18 more
core   +1 more source